NICE Rejects Gilead Sciences’ Yescarta on Cost Concerns The United Kingdom’s government-funded health service isn’t being so nice to Gilead Sciences’ CAR-T blood cancer treatment Yescarta. The country’s National Institute for Health and Care Excellence (NICE) said the therapy is too expensive for th...
Find MoreAstraZeneca dragout Entasis files to fund antibiotic phase 3 for USD 86 Million IPO Massachusetts-based Entasis Therapeutics has spun out to raise up to USD 86 Million through an IPO. The AstraZeneca spinout is attempting to fund a phase 3 trial of a drug to overcome bacterial resistance to beta-lactams. In 2015, ...
Find MoreObesity and diabetes are a global epidemic contributing to an increasing prevalence of related systemic disorders, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Nonalcoholic Steatohepatitis (NASH) is a subtype of NAFLD (Nonalcoholic Fatty Liver disease) that is charact...
Find MoreNASH is defined as the most common form of Nonalcoholic fatty liver disease (NAFLD). The disease is characterized by a spectrum of symptoms including simple steatosis, increased levels of fibrosis, and cirrhosis of the liver. NASH can also result in advanced fibrosis, NASH cirrhosis, and NASH Decompensated Cirrhosi...
Find MoreGilead Sciences has recently launched a highly effective hepatitis C drug Sovaldi at a whopping price of USD 84,000 per treatment course at the same time when ‘How to price a cure’ discussion has entered the pharma industry. Gilead bought a launch-ready drug and launched it very quietly hoping that it's very cost-ef...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.